Background: Depression is a major cause of chronic disability throughout the world and an important cardiovascular risk factor, increasing the relative risk of coronary artery disease as well as rates of cardiovascular morbidity and mortality.
depression therapy for a prolonged period (six months). The findings will contribute to the understanding of the therapeutic effects of vitamin D supplementation on the management of depression and can help guide public policies directed toward vitamin supplementation for the reduction of cardiovascular risk. Trial registration:
Proof: http://www.ensaiosclinicos.gov.br/rg/. Number: RBR-6yj8sj / UTN Number: U1111-1217-9237 (July 23, 2018) Background Depression is a major cause of disability throughout the world, with a report of more than 300 million individuals affected in 2015, which corresponds to 4.4% of the global population [1] . Depression is also considered a cardiovascular risk factor, increasing the relative risk of coronary artery disease as well as rates of cardiovascular morbidity and mortality [2] [3] [4] . As depression from the physiopathological standpoint is a complex disorder that likely has multiple subtypes and etiologies, calcitriol (vitamin D) could play an important role in this condition [5] .
Vitamin D receptors have been identified in areas of the brain involved with depression, such as the prefrontal cortex, hypothalamus and substantia nigra.
Therefore, this vitamin is considered a neurosteroid. Vitamin D has also been found to increase the expression of genes that code tyrosine hydroxylase, which is a precursor of dopamine and norepinephrine [5] . Moreover, calcitriol may provide significant protection against the effects of the reduction in neurotransmitters (dopamine and serotonin) at neurotoxic doses of methamphetamine. Calcitriol has been found to play an important role in neurons in both in vitro and in vivo studies and has the ability to regulate trophic factors and protect against various lesions 4 [6] . Schneider [7] suggested that psychiatric disorders, such as schizophrenia, alcoholism and depression, may be associated with low serum levels of 25hydroxyvitamin D [25 (OH) D]. Recent studies report that vitamin D deficiency may be associated with an increase in depression rates from 8 to 14% [8] [9] [10] [11] [12] .
A placebo-controlled, double-blind study demonstrated that vitamin D supplementation for eight weeks was beneficial at reducing symptoms of depression, but the difference was non-significant (p = 0.06). Despite this finding, the authors report improvements in insulinemia and the homeostasis of pancreatic β cells as well as an effect on the total antioxidant capacity of the plasma [13] .
Recent meta-analyses conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) report a statistically significant reduction in depressive symptoms and clinically significant reduction in depression following vitamin D supplementation [14, 15] .
Therefore, this article presents the protocol for a randomized, placebo-controlled, double-blind, clinical trial with the aim of evaluating the therapeutic effects of vitamin D (50,000 IU per week for six months) on depression and cardiovascular risk factors in patients with depression in care at psychiatric clinics of two university hospitals in northeast Brazil compared to a control group (placebo once per week for six months). The hypothesis is that vitamin D supplementation is capable of improving depressive symptoms and lowering the risk of suicide and cardiovascular risk in patients with depression.
Methods
This protocol study was guided by the SPIRIT recommendations ( Figure 1 -flowchart of study). The proposed prospective, randomized, placebo-controlled, double-blind trial has been duly registered (http://www.ensaiosclinicos.gov.br/rg/; trial registry number: RBR-6yj8sj/UTN number: U1111-1217-9237 (July 23, 2018). All participants will be recruited from the psychiatric outpatient clinics of Universidade de Pernambuco (UPE) and Universidade Federal de Pernambuco (UFPE).
We will evaluate 224 male and female adults (age range: 18 to 60 years) with depression under routine care at the UFPE and UPE psychiatric clinics for a period of six months.
Eligibility criteria
Individuals between 18 and 60 years of age with a diagnosis of depression (score > 6 points on the Montgomery-Asberg Depression Rating Scale) [16] , independently of sex or gender.
The participants will need to have a diagnosis of depression provided by a psychiatrist and based on the ICD-10 [17] , such as F33.0 (recurring mild depression), The patients may be taking an antidepressant prescribed by their psychiatrists. No restriction will be imposed regarding the type of antidepressant medication. The severity of the disease may be mild, moderate or severe, as evaluated by the psychiatrist.
Individuals with cognitive impairment (determined using the Mini-Mental Health
Examination [18] , those already supplementing with vitamin D, those with a past history of psychiatric comorbidities, chronic kidney disease, hypercalcemia or neoplasms and pregnant or nursing women will be excluded from the study.
Operational procedures
The allocation of the participants to the different groups will be masked. Thus, the patients and investigator will be unaware of which capsule (vitamin D or placebo) the patients are taking. This procedure is necessary to avoid observation bias during the clinical-laboratorial follow up and to maintain complete impartiality in the evaluation of the effects.
All instructions will be precise and written in the form of a manual to ensure the execution of all procedures determined for the clinical trial, including patient recruitment, allocation to the study groups, administration of the intervention, record systems, criteria for interrupting the intervention, etc. All activities to be performed during the clinical trial will be previously established in the form of a task list distributed to the investigation team.
The initial evaluation will consist of the filling out of the identification chart, sociodemographic inventory, standardized medical chart with patient history, physical and cardiological examinations, a questionnaire addressing the practice of activities involving exposure to sunlight, standardized statement of informed consent, a structured interview addressing depression with the use of the Montgomey-Asberg Depression Rating Scale and a scale addressing the risk of suicide, and the recording of the results of laboratory and cardiological exams. The researcher will accompany the examinations and administration of the depression and suicidal risk scales.
The laboratorial exams will be conducted at the laboratory of the hospital in which the study will be developed. Venous blood (10 ml) will be collected from a peripheral vein for the determination of fasting glucose, cholesterol (total and fractions), urea, creatinine, total proteins, albumin, homocysteine, ultrasensitive Creactive protein, lipoprotein A, ionic calcium and phosphorus as well as hormonal levels of total and free testosterone, estradiol, estriol, luteinizing hormone, folliclestimulating hormone, thyroid-stimulating hormone, triiodothyronine, free tetraiodothyronine, cortisol, concentration of 25-hydroxyvitamin D and parathyroidstimulating hormone upon admission to the study and each ninety days for a total period of six months. Urine will be collected every 90 days for the determination of 24-hour calciuria and microalbuminuria. The following laboratorial equipment will be used for the determinations: Architect C8000 for vitamin D and hormone concentrations and CMD 800 with ISE (Wiener Group) for the biochemical concentrations.
Cardiological and imaging exams (electrocardiography, Doppler echocardiography, stress test, electrocardiographic monitoring and Doppler ultrasound of the carotid and vertebral arteries) will be performed at the hospital in which the study will be developed.
When the participants return with the exam results, simple randomization (heads or tails) will be performed for the allocation to the different groups: 112 individuals in the vitamin D3 group and 112 in the placebo group. A nurse at the clinic will administer the vitamin D3 and placebo. The capsules will have the same size and color (compounded for the clinical trial) and the nurse will also be blinded to the allocation of the patients to the different groups.
The researchers will evaluate the participants every 90 days. Each evaluation will involve the clinical and cardiological examinations with the electrocardiogram and laboratorial exams selected for the study.
The final evaluation will occur after six months of intervention. The participants will be submitted to psychiatric (Montgomery-Asberg Depression Rating Scale) [16] and Columbia-Suicide Severity Rating Scale [19] , clinical and cardiological examinations as well as the laboratorial exams, electrocardiography, Doppler echocardiography, stress test, 24-h Holter and Doppler ultrasound of carotid and vertebral arteries.
As the region in which the clinical trial will be conducted is sunny throughout the entire year, with an absence of well-defined climatic seasons, seasonality will not exert an influence on exposure to sunlight or the synthesis of vitamin D [20] .
Calculation of sample size
The following were considered for the determination of the sample size:
a) The comparative objective will be an improvement in the depression score among the patients taking and those not taking vitamin D. We considered the success percentages obtained in a study on vitamin D [21] , who found 69.2% and 65% improvements in the depression scale scores, respectively; b) 5.0% acceptable rate of error; 80.0% power; ratio of 1.00 between the two groups.
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The necessary sample size for each group was 112 patients (total of 224 patients).
The calculation was performed using the EPI-INFO program, version 6.04.
Reduction of risk of bias
The dose of vitamin D for supplementation considered for the study (50.000 IU weekly) meets the pre-established criteria in previous trials that have presented positive results in the reduction of depressive symptoms [22] . The aim of considering this variable is to minimize the potential bias. When administered with the prescribed posology, vitamin D3 is quite safe. Doses up to 10,000 IU per day for five months induced no signs of toxicity, such as hypercalcemia and hypercalciuria [23, 24] .
Collection and management of data, including meta-data
The characteristics and procedures adopted for each test group are described below:
Group 1 -Intervention: 112 participants will receive vitamin D3 supplementation (ADDERA D3, MANTECORP Laboratory) at a dose of 50,000 IU per week for six months.
Group 2 -Placebo: 112 participants will receive a placebo capsule (compounded by the pharmaceutical laboratory of the Federal University of Pernambuco) once a
week for six months.
The groups will be submitted to five evaluations on the first day and after six months of intervention:
1-Questionnaire addressing sociodemographic characteristics • The questionnaire will be administered to the participants in the form of an interview and filled in by the researcher. The following data will be recorded:
identification number attributed to the participant, age, sex, schooling, marital 10 status, ethnicity and religion.
-Brazilian Economic Classification Criteria (BECC) -2011 established by the

Brazilian Association of Research Companies [25]
• The BECC is an economic segmentation instrument that uses a survey of residential characteristics (presence and quantity of household items of comfort and degree of schooling of the head of the family) to differentiate the population (Appendix C).
• Points are attributed to each household characteristic and the total is used to classify economic strata from highest to lowest class: A1, A2, B1, B2, C1, C2, D, E
[25].
-Severity of depression: determined through a structured clinical interview.
• Montgomery-Asberg Depression Rating Scale [16] will be administered at the beginning of the study and after six months of intervention.
4-Assessment of Risk of Suicide
• Columbia-Suicide Severity Rating Scale [19] will be administered to assess presence and intensity of suicidal ideation and suicidal behavior.
5-Cardiovascular risk factors
• Systemic arterial hypertension -based on systolic and diastolic blood pressure levels [26] ;
• Dyslipidemia (total cholesterol total, HDL, LDL, triglycerides) [27] ;
• Coronary artery disease: coronary calcium > 100 th or > 75 th percentile for age or sex, cardiac stress test or myocardial scintillography with signs of myocardial ischemia [28] ;
• Cerebrovascular accident (stroke): clinical condition or suggestive imaging exam;
• Obstructive peripheral arterial disease: ankle-brachial pressure index < 0.9; arterial stenosis detected by ultrasound of lower limbs [29] ;
• Carotid atherosclerosis: stenosis/thickening of carotid artery [27] ;
• Heart failure: left ventricular hypertrophy or reduction in systolic function of the left ventricle or diastolic dysfunction detected by Doppler echocardiography [30] ;
• Arrythmia: detected by resting electrocardiography, 24-hour Holter or stress test;
• Diabetes mellitus: reduction in glucose tolerance and resistance to insulin (fasting glucose, A1C hemoglobin, oral glucose tolerance test, basal insulin, insulin curve, homeostatic model assessment) [31, 32] ;
• Serum markers of cardiovascular risk (ultra-sensitive C reactive protein,
homocysteine, lipoprotein A [27];
• Hyperthyroidism or hyporthyroidism (ultra-sensitive TSH, free T4, free T3) [33, 34] ;
• Chronic kidney disease: albuminuria, measured by glomerular filtration rate and calculated based on the Chronic Kidney Disease Epidemiology Collaboration [35] ;
• Hyperparathyroidism (HPT, phosphorus) [36] .
Data analysis
The data will be analyzed using statistical measures: mean and standard deviation values for numerical variables and percentage frequencies for categorical variables. The unpaired and paired t-tests will be used in situations for which the data exhibit normal distribution, whereas the Mann-Whitney test and Wilcoxon test for paired variables will be used in situations in which normality has been rejected. The Shapiro-Wilk test will be used to determine the normality of the data and Levene's F test will be used to determine equality of variances.
The margin of error used in the decisions of the statistical tests will be 5% and 95% confidence intervals will be calculated. The data will be entered onto an EXCEL spread sheet and the Statistical Package for the Social Sciences (SPSS version 23) will be used for all statistical calculations.
Ethical considerations
The 13-Hyperparathyroidism (HPT): reduction in or normalization of serum levels of HPT [36] .
Discussion
The aim of this protocol is to describe procedures related to the development of a clinical trial on the therapeutic effects of vitamin D (50,000 IU per week for six months) on depression and cardiovascular risk factors in patients with depression in care at psychiatric clinics of two universities compared to a control group receiving a placebo once a week for the same period of time.
Vitamin D supplementation in patients with depression has been shown to improve depressive symptoms, as demonstrated in three systematic reviews [14, 15, 39] .
Vitamin D supplementation had a moderate, statistically significant effect in patients with clinically significant depressive symptoms or depressive disorder [15] .
In another systematic review, the meta-analysis of all studies without flaws demonstrated a statistically significant improvement in depression following vitamin D supplementation, with an effect size comparable to that of antidepressant medication [12] . With the aim of evaluating the potential of nutraceuticals, including vitamin D, as adjuvants to antidepressant therapy, an important systematic review and meta-analysis conducted in 2016 obtained positive results, suggesting the modulating action of nutraceuticals with regards to several neurochemical pathways involved in depression [39] .
The combination of vitamin D and traditional antidepressant treatment may lead to the optimization of therapy for depression with greater tolerability and without additional side effects. Moreover, the therapeutic effects of vitamin D on cardiovascular risk factors may have an impact on cardiovascular risk.
The dose of vitamin D considered in the proposed study (50,000 IU per week) meets the criteria established in a previous trial that reported positive results regarding the reduction in depressive systems [22] . The aim of using this does is to minimize potential bias. The risk of toxicity with this dose is minimal, as doses up to 10,000 IU per day (70,000 IU per week) for five months did not induce signs of toxicity in a previous study, such as hypercalcemia and hypercalciuria [23] .
The results of the proposed clinical trial could contribute to the understanding of the therapeutic effects of vitamin D supplementation on depression and the risk of suicide. This study could also underscore the importance of investigating serum vitamin D levels in patients with depression. Regarding cardiovascular risk, the results of the study could assist in the implementation of the evaluation of cardiovascular risk factors in patients with depression in an attempt to reduce morbidity and mortality rates in this population. Another potential benefit of this clinical trial is the contribution to public policies addressing the importance of serum levels of vitamin D to the identification of patients with deficiencies in this vitamin and promote its supplementation for the prevention of cardiovascular events, depression and suicide, which lead to higher rates of morbidity and mortality throughout the world.
The results and conclusions of this clinical trial will be sent to national and international symposiums as well as peer-reviewed journals. Access, re-use and data sharing 16 The datasets used and analyzed during the study will be made available by the author through any reasonable request.
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The datasets used and analyzed during the study will be in the custody of the researcher in charge of the project.
Limitations
The study will be conducted at only two public universities. The participants will also need to visit the outpatient clinics on a weekly basis to receive the medication, which could lead to absenteeism. To circumvent this problem, a research staff member can visit the patient's home in cases of failure to appear at the clinics.
The antidepressant medications will be determined by the psychiatrist providing care to the patient. Thus, the researchers of the present clinical trial will have no control over the type or dosage of the antidepressants prescribed. This lack of standardization of antidepressant medications may be a source of bias in the research. 
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